\nGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2020.\n<\/p>\n
2020 Financial Highlights<\/b><\/p>\n 2020 Business and Recent Highlights<\/b><\/p>\n Note: \n\u201cIn 2020, despite the challenges caused by the global pandemic, we completed a successful IPO and made significant commercial and clinical progress across all of our business lines. We delivered robust revenue growth with 31.3% year-over-year increase, and we are particularly pleased with the commercial uptakes of HCCscreenTM<\/sup> and our IVD products. Compared to a year ago, our gross margin expanded to 61.3% from 44.8%, and we also markedly improved our SG&A operational efficiencies,\u201d remarked Mr. Sizhen Wang, co-founder and CEO of Genetron Health. \u201cWe announced new HCCscreenTM<\/sup> data from our prospective cohort study, which showed overall better sensitivity data, and comparable specificity data versus the standard-of-care. We are encouraged by the further validation of this leading liquid-biopsy early detection assay, and will move forward to initiate an NMPA registrational study in the second quarter of this year.\u201d\n<\/p>\n \n\u201cIn 2021, based on the current environment and providing no further major COVID-19-related disruptions in our key markets, we are forecasting our sales to grow around 45% to 47% to reach RMB615 million to RMB625 million. On the pipeline front, we plan to provide case-control early screening data for colorectal cancer this year. Thanks to our Mutation CapsuleTM<\/sup> early screening technology, we are advancing well on our plans to expand our single-cancer assay to become a multi-cancer product. We also continue to make progress on our MRD projects in liver and colorectal cancers. Overall, Genetron Health is well-positioned to capture market share in the fast-growing precision oncology sector, and we are excited about our growth prospects. More importantly, we remain highly committed to developing innovative products that would benefit cancer patients and save more lives,\u201d concluded Mr. Wang.\n<\/p>\n Fourth Quarter 2020 Unaudited Preliminary Financial Results<\/b><\/p>\n \nTotal revenue for the fourth quarter 2020 increased by 30.1% to RMB133.9 million (US$20.5 million) from RMB102.9 million in the same period of 2019.\n<\/p>\n \nDiagnosis and monitoring revenue increased by 44.0% to RMB123.5 million (US$18.9 million) in the fourth quarter 2020 from RMB85.8 million in the same period of 2019. The increase was driven by the growth in the revenues generated from both the provision of LDT services, particularly in early screening, and the sale of IVD products.\n<\/p>\n Contracted in-hospital partners<\/span><\/b><\/p>\n<\/td>\n<\/tr>\n (as of the end of the period indicated)<\/span><\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n 2019<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 1Q20<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2Q20<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 3Q20<\/b><\/p>\n<\/td>\n 4Q20<\/b><\/p>\n<\/td>\n<\/tr>\n IVD In-hospital partners<\/b><\/p>\n<\/td>\n \n13\n<\/p>\n<\/td>\n \n13\n<\/p>\n<\/td>\n \n18\n<\/p>\n<\/td>\n \n20\n<\/p>\n<\/td>\n \n22\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n 2019<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 1Q20<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2Q20<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 3Q20<\/b><\/p>\n<\/td>\n 4Q20<\/b><\/p>\n<\/td>\n<\/tr>\n Total in-hospital partners(1)<\/sup><\/b><\/p>\n<\/td>\n \n25\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n26\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n35\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n38\n<\/p>\n<\/td>\n \n40\n<\/p>\n<\/td>\n<\/tr>\n \nNote:\n<\/p>\n \n(1) The number of total in-hospital partners include both sales of LDT services and IVD products.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nRevenue generated from development services decreased by 39.0% to RMB10.5 million (US$1.6 million) in the fourth quarter 2020, from RMB17.2 million in the same period of 2019. The change mainly resulted from the decrease in sequencing services, reflecting the continued adjustment of the Company\u2019s business strategy towards biopharmaceutical services. Biopharmaceutical revenue increased in the fourth quarter of 2020 compared to the same period of 2019.\n<\/p>\n \nDespite higher revenue, cost of revenue decreased by 12.8% to RMB49.8 million (US$7.6 million) for the three months ended December 31, 2020, compared to RMB57.1 million in the same period of 2019. These decreases were primarily due to economies of scale and lower cost of certain reagents.\n<\/p>\n \nGross profit increased by 83.6% to RMB84.1 million (US$12.9 million) in the fourth quarter 2020 from RMB45.8 million in the same period of 2019. Gross margin increased to 62.8% for the fourth quarter of 2020, compared to 44.5% in the same period of 2019.\n<\/p>\n \nOperating expenses increased by 32.5% to RMB173.0 million (US$26.5 million) for the three months ended December 31, 2020, from RMB130.6 million in the same period of 2019.\n<\/p>\n \nSelling expenses increased by 4.3% to RMB72.0 million (US$11.0 million) in the fourth quarter 2020 from RMB69.0 million in the same period of 2019. Selling expenses as a percentage of revenues decreased to 53.7% in the fourth quarter 2020 from 67.0% in the same period of 2019. The decrease was primarily due to better scale and different revenue mix.\n<\/p>\n \nAdministrative expenses increased by 54.5% to RMB 44.3 million (US$6.8 million) in the fourth quarter 2020 from RMB28.7 million in the same period of 2019. Administrative expenses as a percentage of revenues increased to 33.1% in the fourth quarter 2020 from 27.9% in the fourth quarter 2019. The increases were mainly due to more headcount and share-based compensation, as well as higher professional fees.\n<\/p>\n \nResearch and development expenses increased by 63.7% to RMB53.0 million (US$8.1 million) in the fourth quarter 2020 from RMB32.4 million in the same period of 2019. Research and development expenses as a percentage of revenues increased to 39.5% in the fourth quarter of 2020 from 31.4% in the same period of 2019. The increases were driven by continued innovation efforts including product development, clinical trial activities, as well as higher headcount and share-based compensation.\n<\/p>\n \nAs a result of the above, operating loss was RMB88.9 million (US$13.6 million) for the three months ended December 31, 2020, compared to RMB84.8 million for the three months ended December 31, 2019.\n<\/p>\n \nFinance income increased to RMB15.6 million (US$2.4 million) in the fourth quarter 2020 from finance costs of RMB6.1 million in the same period of 2019. The increase was driven by the foreign currency exchange gain.\n<\/p>\n \nLoss for the period was RMB73.2 million (US$11.2 million) for the three months ended December 31, 2020, compared to RMB134.8 million for the three months ended December 31, 2019.\n<\/p>\n \nNon-IFRS loss for the period, defined as loss for the period excluding share-based compensation expenses, fair value change and other loss of financial instruments with preferred rights, was RMB 62.5 million (US$9.6 million) for the three months ended December 31, 2020, compared to RMB86.4 million for the three months ended December 31, 2019. Please refer to the section in this press release titled “Non-IFRS Financial Measures” for details.\n<\/p>\n \nBasic loss per ordinary sharewas RMB0.16 (US$0.02) for the fourth quarter of 2020, compared with a basic loss per ordinary share of RMB1.06 for the same period of 2019. Excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights, non-IFRS basic loss per ordinary share was RMB0.14 (US$0.02) for the fourth quarter of 2020, compared with non-IFRS basic loss per ordinary share of RMB0.68 for the same period of 2019. Diluted loss per ordinary share is equivalent to basic loss per ordinary share. Each ADS represents of five ordinary shares, par value US$0.00002 per share. Please refer to the section in this press release titled “Non-IFRS Financial Measures” for details.\n<\/p>\n Full Year 2020 Financial Results<\/b><\/p>\n \nTotal revenue for the full year 2020 increased by 31.3% to RMB424.5 million (US$65.1 million) from RMB323.4 million in 2019.\n<\/p>\n \nDiagnosis and monitoring revenue increased by 43.1% to RMB385.7 million (US$59.1 million) in 2020 from RMB269.5 million in 2019. The increase was driven by the growth in the revenues generated from both the provision of LDT services and the sale of IVD products.\n<\/p>\n \nRevenue generated from development services decreased by 28.1% to RMB38.8 million (US$5.9 million) in 2020, from RMB53.9 million in 2019. The change mainly resulted from the decrease in sequencing services, reflecting the continued adjustment of the Company\u2019s business strategy towards biopharmaceutical services. Biopharmaceutical revenue increased in 2020 compared to 2019.\n<\/p>\n \nDespite higher revenue, cost of revenue decreased by 7.9% to RMB164.3 million (US$25.2 million) for the twelve months ended December 31, 2020, compared to RMB178.4 million in 2019. These decreases were primarily due to economies of scale and reduced cost of certain reagents.\n<\/p>\n \nGross profit increased by 79.5% to RMB260.2 million (US$39.9 million) in 2020 from RMB145.0 million in 2019. Gross margin increased to 61.3% for the full year 2020, compared to 44.8% in 2019. During 2020, gross margin improvements were seen across all major business lines, mainly attributable to improved scale, operational optimization, and better product mix.\n<\/p>\n \nOperating expenses increased by 17.0% to RMB528.6 million (US$81.0 million) in 2020 from RMB451.9 million in the same period of 2019.\n<\/p>\n \nSelling expenses decreased by 2.6% to RMB247.0 million (US$37.8 million) in 2020 from RMB253.6 million in 2019, primarily due to a stable number of sales and marketing personnel. Selling expenses as a percentage of revenues decreased to 58.2% in 2020 from 78.4% in 2019.\n<\/p>\n \nAdministrative expenses increased by 7.8% to RMB126.3 million (US$19.4 million) in 2020 from RMB117.2 million in 2019, primarily due to an increase in headcount and professional fees. Administrative expenses as a percentage of revenues decreased to 29.8% in 2020 from 36.2% in 2019.\n<\/p>\n \nResearch and development expenses increased by 62.5% to RMB149.0 million (US$22.8 million) in 2020 from RMB91.7 million in 2019. The increases were driven by continued innovation efforts inclusive of development of new products and technologies, clinical trial activities, higher headcount and share-based compensation. Research and development expenses as a percentage of revenues increased to 35.1% in 2020 from 28.4% in 2019.\n<\/p>\n \nAs a result of the above, operating loss improved to RMB268.4 million (US$41.1 million) for 2020, from RMB306.9 million in 2019.\n<\/p>\n \nFinance income increased to RMB22.7 million (US$3.5 million) in 2020 from finance costs of RMB9.2 million in 2019. The increase was driven by the foreign currency exchange gain.\n<\/p>\n \nWith the significant increase of valuation directly observable through the IPO offering price, the fair value loss of financial instruments with preferred rights recorded was significantly higher amounted to RMB2,823.4 million in 2020. Upon IPO, all preferred shares were converted to ordinary shares and there was no further impact after the consummation of the IPO.\n<\/p>\n \nLoss for the period was RMB3.1 billion (US$470.4 million) for 2020, compared to RMB676.0 million in 2019.\n<\/p>\n \nNon-IFRS loss for the period, defined as loss for the period excluding share-based compensation expenses, fair value change and other loss of financial instruments with preferred rights, was RMB215.7 million (US$33.1 million) for 2020, compared to RMB280.2 million in 2019. Please refer to the section in this press release titled “Non-IFRS Financial Measures” for details.\n<\/p>\n \nBasic loss per ordinary sharewas RMB10.18 (US$1.56) for 2020, compared with a basic loss per ordinary share of RMB5.41 for the same period of 2019. Excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights, non-IFRS basic loss per ordinary share was RMB0.72 (US$0.11) for 2020, compared with non-IFRS basic loss per ordinary share of RMB2.24 for the same period of 2019. Diluted loss per ordinary share is equivalent to basic loss per ordinary share. Each ADS represents of five ordinary shares, par value US$0.00002 per share. Please refer to the section in this press release titled “Non-IFRS Financial Measures” for details.\n<\/p>\n \nCash, cash equivalents and financial assets at fair value were RMB1516.1 million (US$232.3 million) as of December 31, 2020.\n<\/p>\n 2021 Financial Guidance<\/b><\/p>\n \nBased on the current environment and providing no further major COVID-19-related disruptions in our key markets, Genetron Health expects 2021 revenue to be around RMB615 million to RMB625 million, representing around 45%-47% growth over 2020.\n<\/p>\n Conference Call<\/b><\/p>\n \nA conference call and webcast to discuss the results will be held at 8:30 a.m. U.S. Eastern Time on March 25, 2021 (or at 8:30 pm Beijing Time on March 25, 2021). Interested parties may listen to the conference call by dialing numbers below:\n<\/p>\n \nUnited States: +1-845-675-0437 \nParticipants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes.\n<\/p>\n \nThe replay will be accessible through April 2, 2021, by dialing the following numbers:\n<\/p>\n \nUnited States: +1-855-452-5696 \nA simultaneous webcast of the conference call will be available on the “News and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com.\n<\/p>\n Exchange Rate Information <\/b><\/p>\n \nAll translations made in the financial statements or elsewhere in this press release made from RMB into United States dollars (\u201cUS$\u201d) are solely for convenience and calculated at the rate of US$1.00=RMB6.525, representing the exchange rate as of December 31, 2020, set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate, or at any other rate, on December 31, 2020.\n<\/p>\n Non-IFRS Financial Measures <\/b><\/p>\n \nThe Company uses non-IFRS loss and non-IFRS loss per ordinary share for the year\/period, which are non-IFRS financial measures, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that non-IFRS loss and non-IFRS loss per ordinary share help identify underlying trends in the Company’s business that could otherwise be distorted by the effect of certain expenses that the Company includes in its loss for the year\/period. The Company believes that non-IFRS loss and non-IFRS loss per ordinary share for the year\/period provide useful information about its results of operations, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by its management in its financial and operational decision-making.\n<\/p>\n \nNon-IFRS loss and non-IFRS loss per ordinary share for the year\/period should not be considered in isolation or construed as an alternative to operating profit, loss for the year\/period or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review non-IFRS loss and non-IFRS loss per ordinary share for the year\/period and the reconciliation to its most directly comparable IFRS measures. Non-IFRS loss and non-IFRS loss per ordinary share for the year\/period presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company’s data. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.\n<\/p>\n \nNon-IFRS loss and non-IFRS loss per ordinary share for the year\/period represent loss for the year\/period excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights (if applicable).\n<\/p>\n \nPlease see the \u201cUnaudited Non-IFRS Financial Measures\u201d included in this press release for a full reconciliation of non-IFRS loss for the year\/period to loss for the year\/period and non-IFRS loss per ordinary share for the year\/period to loss per ordinary share for the year\/period.\n<\/p>\n About Genetron Holdings Limited<\/b><\/p>\n \nGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.\n<\/p>\n Safe Harbor Statement <\/b><\/p>\n \nThis press release contains forward-looking statements. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company\u2019s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as \u201cmay\u201d, \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cis\/are likely to\u201d or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company\u2019s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.\n<\/p>\n GENETRON HOLDINGS LIMITED<\/b><\/p>\n<\/td>\n<\/tr>\n UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS<\/b><\/p>\n<\/td>\n<\/tr>\n For the three months ended<\/b><\/p>\n<\/td>\n For the year ended<\/b><\/p>\n<\/td>\n<\/tr>\n December 31, 2019<\/b><\/p>\n<\/td>\n December 31, 2020<\/b><\/p>\n<\/td>\n December 31, 2019<\/b><\/p>\n<\/td>\n December 31, 2020<\/b><\/p>\n<\/td>\n<\/tr>\n RMB\u2019000<\/b><\/p>\n<\/td>\n RMB\u2019000<\/b><\/p>\n<\/td>\n US$\u2019000<\/b><\/p>\n<\/td>\n RMB\u2019000<\/b><\/p>\n<\/td>\n RMB\u2019000<\/b><\/p>\n<\/td>\n US$\u2019000<\/b><\/p>\n<\/td>\n<\/tr>\n Revenue <\/b><\/p>\n<\/td>\n \n102,940\n<\/p>\n<\/td>\n \n133,944\n<\/p>\n<\/td>\n \n20,528\n<\/p>\n<\/td>\n \n323,425\n<\/p>\n<\/td>\n \n424,485\n<\/p>\n<\/td>\n \n65,055\n<\/p>\n<\/td>\n<\/tr>\n \nCost of revenue\n<\/p>\n<\/td>\n \n(57,120)\n<\/p>\n<\/td>\n \n(49,820)\n<\/p>\n<\/td>\n \n(7,635)\n<\/p>\n<\/td>\n \n(178,435)\n<\/p>\n<\/td>\n \n(164,268)\n<\/p>\n<\/td>\n \n(25,175)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n Gross profit<\/b><\/p>\n<\/td>\n \n45,820\n<\/p>\n<\/td>\n \n84,124\n<\/p>\n<\/td>\n \n12,893\n<\/p>\n<\/td>\n \n144,990\n<\/p>\n<\/td>\n \n260,217\n<\/p>\n<\/td>\n \n39,880\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n \nSelling expenses\n<\/p>\n<\/td>\n \n(69,009)\n<\/p>\n<\/td>\n \n(71,959)\n<\/p>\n<\/td>\n \n(11,028)\n<\/p>\n<\/td>\n \n(253,558)\n<\/p>\n<\/td>\n \n(246,959)\n<\/p>\n<\/td>\n \n(37,848)\n<\/p>\n<\/td>\n<\/tr>\n \nAdministrative expenses\n<\/p>\n<\/td>\n \n(28,698)\n<\/p>\n<\/td>\n \n(44,349)\n<\/p>\n<\/td>\n \n(6,797)\n<\/p>\n<\/td>\n \n(117,169)\n<\/p>\n<\/td>\n \n(126,318)\n<\/p>\n<\/td>\n \n(19,359)\n<\/p>\n<\/td>\n<\/tr>\n \nResearch and \n(32,361)\n<\/p>\n<\/td>\n \n(52,969)\n<\/p>\n<\/td>\n \n(8,118)\n<\/p>\n<\/td>\n \n(91,697)\n<\/p>\n<\/td>\n \n(148,999)\n<\/p>\n<\/td>\n \n(22,835)\n<\/p>\n<\/td>\n<\/tr>\n \nNet impairment losses on \n(1,997)\n<\/p>\n<\/td>\n \n(12,746)\n<\/p>\n<\/td>\n \n(1,953)\n<\/p>\n<\/td>\n \n(2,733)\n<\/p>\n<\/td>\n \n(14,843)\n<\/p>\n<\/td>\n \n(2,275)\n<\/p>\n<\/td>\n<\/tr>\n \nOther income\/(loss) – net\n<\/p>\n<\/td>\n \n1,484\n<\/p>\n<\/td>\n \n9,039\n<\/p>\n<\/td>\n \n1,385\n<\/p>\n<\/td>\n \n13,297\n<\/p>\n<\/td>\n \n8,526\n<\/p>\n<\/td>\n \n1,307\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n \nOperating expenses\n<\/p>\n<\/td>\n \n(130,581)\n<\/p>\n<\/td>\n \n(172,984)\n<\/p>\n<\/td>\n \n(26,511)\n<\/p>\n<\/td>\n \n(451,860)\n<\/p>\n<\/td>\n \n(528,593)\n<\/p>\n<\/td>\n \n(81,010)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n Operating loss<\/b><\/p>\n<\/td>\n \n(84,761)\n<\/p>\n<\/td>\n \n(88,860)\n<\/p>\n<\/td>\n \n(13,618)\n<\/p>\n<\/td>\n \n(306,870)\n<\/p>\n<\/td>\n \n(268,376)\n<\/p>\n<\/td>\n \n(41,130)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n \nFinance income\n<\/p>\n<\/td>\n \n2,045\n<\/p>\n<\/td>\n \n17,268\n<\/p>\n<\/td>\n \n2,646\n<\/p>\n<\/td>\n \n2,483\n<\/p>\n<\/td>\n \n28,330\n<\/p>\n<\/td>\n \n4,341\n<\/p>\n<\/td>\n<\/tr>\n \nFinance costs\n<\/p>\n<\/td>\n \n(8,101)\n<\/p>\n<\/td>\n \n(1,630)\n<\/p>\n<\/td>\n \n(250)\n<\/p>\n<\/td>\n \n(11,704)\n<\/p>\n<\/td>\n \n(5,627)\n<\/p>\n<\/td>\n \n(862)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n \nFinance (costs)\/income – net\n<\/p>\n<\/td>\n \n(6,056)\n<\/p>\n<\/td>\n \n15,638\n<\/p>\n<\/td>\n \n2,396\n<\/p>\n<\/td>\n \n(9,221)\n<\/p>\n<\/td>\n \n22,703\n<\/p>\n<\/td>\n \n3,479\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n \nFinancial instruments with preferred rights\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n– loss on fair value changes\n<\/p>\n<\/td>\n \n(17,439)\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n(333,401)\n<\/p>\n<\/td>\n \n(2,823,370)\n<\/p>\n<\/td>\n \n(432,700)\n<\/p>\n<\/td>\n<\/tr>\n \n– other loss\n<\/p>\n<\/td>\n \n(26,542)\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n(26,542)\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n Loss before \n(134,798)\n<\/p>\n<\/td>\n \n(73,222)\n<\/p>\n<\/td>\n \n(11,222)\n<\/p>\n<\/td>\n \n(676,034)\n<\/p>\n<\/td>\n \n(3,069,043)\n<\/p>\n<\/td>\n \n(470,351)\n<\/p>\n<\/td>\n<\/tr>\n \nIncome tax expense\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n Loss for the period<\/b><\/p>\n<\/td>\n \n(134,798)\n<\/p>\n<\/td>\n \n(73,222)\n<\/p>\n<\/td>\n \n(11,222)\n<\/p>\n<\/td>\n \n(676,034)\n<\/p>\n<\/td>\n \n(3,069,043)\n<\/p>\n<\/td>\n \n(470,351)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n<\/tr>\n Loss attributable to:<\/b><\/p>\n<\/td>\n \nOwners of the Company\n<\/p>\n<\/td>\n \n(134,798)\n<\/p>\n<\/td>\n \n(73,222)\n<\/p>\n<\/td>\n \n(11,222)\n<\/p>\n<\/td>\n \n(676,034)\n<\/p>\n<\/td>\n \n(3,069,043)\n<\/p>\n<\/td>\n \n(470,351)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n<\/tr>\n Loss per share <\/b><\/p>\n<\/td>\n RMB<\/b><\/p>\n<\/td>\n RMB<\/b><\/p>\n<\/td>\n USD<\/b><\/p>\n<\/td>\n RMB<\/b><\/p>\n<\/td>\n RMB<\/b><\/p>\n<\/td>\n USD<\/b><\/p>\n<\/td>\n<\/tr>\n \n-Basic and diluted\n<\/p>\n<\/td>\n \n(1.06)\n<\/p>\n<\/td>\n \n(0.16)\n<\/p>\n<\/td>\n \n(0.02)\n<\/p>\n<\/td>\n \n(5.41)\n<\/p>\n<\/td>\n \n(10.18)\n<\/p>\n<\/td>\n \n(1.56)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n<\/tr>\n Loss per ADS<\/b><\/p>\n<\/td>\n \n-Basic and diluted\n<\/p>\n<\/td>\n \n(0.80)\n<\/p>\n<\/td>\n \n(0.12)\n<\/p>\n<\/td>\n \n(50.92)\n<\/p>\n<\/td>\n \n(7.80)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n<\/tr>\n Shares used in loss per \n-Basic and diluted\n<\/p>\n<\/td>\n \n126,699,693\n<\/p>\n<\/td>\n \n456,621,292\n<\/p>\n<\/td>\n \n456,621,292\n<\/p>\n<\/td>\n \n124,894,707\n<\/p>\n<\/td>\n \n301,379,911\n<\/p>\n<\/td>\n \n301,379,911\n<\/p>\n<\/td>\n<\/tr>\n ADS used in loss per ADS computation:<\/b><\/p>\n<\/td>\n \n\u3000\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n \n\u3000\n<\/p>\n<\/td>\n \n\u3000\n<\/p>\n<\/td>\n \n\u3000\n<\/p>\n<\/td>\n<\/tr>\n \n-Basic and diluted\n<\/p>\n<\/td>\n \n91,324,258\n<\/p>\n<\/td>\n \n91,324,258\n<\/p>\n<\/td>\n \n60,275,982\n<\/p>\n<\/td>\n \n60,275,982\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n GENETRON HOLDINGS LIMITED<\/b><\/p>\n<\/td>\n<\/tr>\n UNAUDITED NON-IFRS FINANCIAL MEASURE<\/b><\/p>\n<\/td>\n<\/tr>\n For the three months ended<\/b><\/p>\n<\/td>\n For the year ended<\/b><\/p>\n<\/td>\n<\/tr>\n December 31, 2019<\/b><\/p>\n<\/td>\n December 31, 2020<\/b><\/p>\n<\/td>\n December 31, 2019<\/b><\/p>\n<\/td>\n December 31, 2020<\/b><\/p>\n<\/td>\n<\/tr>\n RMB\u2019000<\/b><\/p>\n<\/td>\n RMB\u2019000<\/b><\/p>\n<\/td>\n US$\u2019000<\/b><\/p>\n<\/td>\n RMB\u2019000<\/b><\/p>\n<\/td>\n RMB\u2019000<\/b><\/p>\n<\/td>\n US$\u2019000<\/b><\/p>\n<\/td>\n<\/tr>\n Loss for the period<\/b><\/p>\n<\/td>\n \n(134,798)\n<\/p>\n<\/td>\n \n(73,222)\n<\/p>\n<\/td>\n \n(11,222)\n<\/p>\n<\/td>\n \n(676,034)\n<\/p>\n<\/td>\n \n(3,069,043)\n<\/p>\n<\/td>\n \n(470,351)\n<\/p>\n<\/td>\n<\/tr>\n \nAdjustments:\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \nShare-based \n4,390\n<\/p>\n<\/td>\n \n10,729\n<\/p>\n<\/td>\n \n1,644\n<\/p>\n<\/td>\n \n35,884\n<\/p>\n<\/td>\n \n29,951\n<\/p>\n<\/td>\n \n4,590\n<\/p>\n<\/td>\n<\/tr>\n \nFinancial instruments \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \n– loss on fair value changes\n<\/p>\n<\/td>\n \n17,439\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n333,401\n<\/p>\n<\/td>\n \n2,823,370\n<\/p>\n<\/td>\n \n432,700\n<\/p>\n<\/td>\n<\/tr>\n \n– other loss\n<\/p>\n<\/td>\n \n26,542\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n26,542\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n \n–\n<\/p>\n<\/td>\n<\/tr>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n \n\u2500\u2500\u2500\u2500\u2500\u2500\u2500\n<\/p>\n<\/td>\n<\/tr>\n Non-IFRS Loss<\/b><\/p>\n<\/td>\n \n(86,427)\n<\/p>\n<\/td>\n \n(62,493)\n<\/p>\n<\/td>\n \n(9,578)\n<\/p>\n<\/td>\n \n(280,207)\n<\/p>\n<\/td>\n \n(215,722)\n<\/p>\n<\/td>\n \n(33,061)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n<\/tr>\n Attributable to:<\/b><\/p>\n<\/td>\n \nOwners of the Company\n<\/p>\n<\/td>\n \n(86,427)\n<\/p>\n<\/td>\n \n(62,493)\n<\/p>\n<\/td>\n \n(9,578)\n<\/p>\n<\/td>\n \n(280,207)\n<\/p>\n<\/td>\n \n(215,722)\n<\/p>\n<\/td>\n \n(33,061)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n<\/tr>\n Non-IFRS loss per share <\/b><\/p>\n<\/td>\n RMB<\/b><\/p>\n<\/td>\n RMB<\/b><\/p>\n<\/td>\n USD<\/b><\/p>\n<\/td>\n RMB<\/b><\/p>\n<\/td>\n RMB<\/b><\/p>\n<\/td>\n USD<\/b><\/p>\n<\/td>\n<\/tr>\n \n-Basic and diluted\n<\/p>\n<\/td>\n \n(0.68)\n<\/p>\n<\/td>\n \n(0.14)\n<\/p>\n<\/td>\n \n(0.02)\n<\/p>\n<\/td>\n \n(2.24)\n<\/p>\n<\/td>\n \n(0.72)\n<\/p>\n<\/td>\n \n(0.11)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n<\/tr>\n Non-IFRS loss per \n\u00a0\n<\/p>\n<\/td>\n \n-Basic and diluted\n<\/p>\n<\/td>\n \n(0.68)\n<\/p>\n<\/td>\n \n(0.10)\n<\/p>\n<\/td>\n \n(3.58)\n<\/p>\n<\/td>\n \n(0.55)\n<\/p>\n<\/td>\n<\/tr>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n<\/p>\n<\/td>\n<\/tr>\n Shares used in non-IFRS loss per ordinary share computation:<\/b><\/p>\n<\/td>\n \n-Basic and diluted\n<\/p>\n<\/td>\n \n126,699,693\n<\/p>\n<\/td>\n \n456,621,292\n<\/p>\n<\/td>\n \n456,621,292\n<\/p>\n<\/td>\n \n124,894,707\n<\/p>\n<\/td>\n \n301,379,911\n<\/p>\n<\/td>\n \n301,379,911\n<\/p>\n<\/td>\n<\/tr>\n ADS used in non-IFRS loss per ADS computation:<\/b><\/p>\n<\/td>\n \n-Basic and diluted\n<\/p>\n<\/td>\n \n91,324,258\n<\/p>\n<\/td>\n \n91,324,258\n<\/p>\n<\/td>\n \n60,275,982\n<\/p>\n<\/td>\n \n60,275,982\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n
\n
\n
\n
(1) <\/b>Non-IFRS loss for the period is defined as loss for the period excluding share-based compensation expenses, fair value change and other loss of financial instruments with preferred rights.\n<\/p>\n\n
\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
\n
China Domestic: 400-620-8038
\n
Hong Kong: +852-3018-6771
\n
International: +65-6713-5090
\n
Conference ID: 5379298\n<\/p>\n
\n
International: +61-2-8199-0299
\n
Conference ID: 5379298\n<\/p>\n\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
development expenses\n<\/p>\n<\/td>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
financial and contract assets\n<\/p>\n<\/td>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
income tax<\/b><\/p>\n<\/td>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
ordinary share computation:<\/b><\/p>\n<\/td>\n\n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n \n
\n
compensation\n<\/p>\n<\/td>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
with preferred rights\n<\/p>\n<\/td>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
ADS (5 ordinary shares equal to 1 ADS)<\/b><\/p>\n<\/td>\n\n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/tr>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n